NAYA Biosciences Inc
NASDAQ:NAYA

Watchlist Manager
NAYA Biosciences Inc Logo
NAYA Biosciences Inc
NASDAQ:NAYA
Watchlist
Price: 2.74 USD 17.09%
Market Cap: 21.9m USD

NAYA Biosciences Inc
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

NAYA Biosciences Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
NAYA Biosciences Inc
NASDAQ:NAYA
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Other Operating Expenses
-$236m
CAGR 3-Years
-6%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Operating Expenses
$3m
CAGR 3-Years
-72%
CAGR 5-Years
-39%
CAGR 10-Years
-28%
Stryker Corp
NYSE:SYK
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

NAYA Biosciences Inc
Glance View

Market Cap
21.9m USD
Industry
Health Care

INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.

NAYA Intrinsic Value
17.49 USD
Undervaluation 84%
Intrinsic Value
Price

See Also

Back to Top